SCHEMBL3706129

SCHEMBL3706129

CC(C)(CNC(=O)c1ccc(NC(=O)N2Cc3ccccc3C2)cc1)N1CCOCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3698404 0.89 NAMPT (1.00) NAMPT
SCHEMBL3699509 0.89 NAMPT (1.00) NAMPT
SCHEMBL3699832 0.89 NAMPT (1.00) NAMPT
SCHEMBL6128294 0.84 NAMPT (0.74) NAMPT
SCHEMBL3707922 0.84 NAMPT (1.00) NAMPT
SCHEMBL3701636 0.82 NAMPT (1.00) NAMPT
SCHEMBL16565833 0.81 ALDH1A1 (0.67) NAMPT
SCHEMBL3698325 0.80 NAMPT (1.00) NAMPT
SCHEMBL3710799 0.80 NAMPT (1.00) NAMPT
SCHEMBL3703231 0.79 NAMPT (1.00) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253562-A1 Nampt Inhibitors ABBVIE INC (US) 2017-09-07 US claimed
US-9302989-B2 NAMPT and rock inhibitors ABBVIE INC. (US) 2016-04-05 US claimed
US-20160031813-A1 Nampt Inhibitors ABBVIE INC. 2016-02-04 US claimed
US-20120122842-A1 NAMPT AND ROCK INHIBITORS ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-10093624-B2 NAMPT and ROCK inhibitors ABBVIE INC. (US) 2018-10-09 US disclosed
EP-2776393-B1 NAMPT INHIBITORS ABBVIE INC (US) 2017-12-20 EP disclosed
US-20170253562-A1 Nampt Inhibitors ABBVIE INC (US) 2017-09-07 US disclosed
US-9302989-B2 NAMPT and rock inhibitors ABBVIE INC. (US) 2016-04-05 US disclosed
US-20160031813-A1 Nampt Inhibitors ABBVIE INC. 2016-02-04 US disclosed
US-20160031880-A1 Nampt and Rock Inhibitors ABBVIE INC. (US) 2016-02-04 US disclosed
EP-2776393-A1 NAMPT INHIBITORS Abbvie Inc. (US) 2014-09-17 EP disclosed
EP-2640698-A1 NAMPT AND ROCK INHIBITORS AbbVie Inc. (US) 2013-09-25 EP disclosed
WO-2013067710-A1 NAMPT INHIBITORS ABBOTT LABORATORIES (US) 2013-05-16 WO disclosed
WO-2012067965-A1 NAMPT AND ROCK INHIBITORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122842-A1 NAMPT AND ROCK INHIBITORS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093624-B2 NAMPT and ROCK inhibitors NAMPT, NNMT, NADK NAMPT 1/4885
US-20120122842-A1 NAMPT AND ROCK INHIBITORS NAMPT, NNMT, NME2 NAMPT 1/4885
US-20170253562-A1 Nampt Inhibitors NAMPT, NNMT, NAPRT NAMPT 1/4885
US-20160031813-A1 Nampt Inhibitors NAMPT, NNMT, NAPRT NAMPT 1/4885
US-20160031880-A1 Nampt and Rock Inhibitors NAMPT, NNMT, NME2 NAMPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.